

Senate Community Affairs Committee

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH PORTFOLIO

Additional Estimates 2016 - 2017, 1 March 2017

Ref No: SQ17-000027

OUTCOME: 4 - Individual Health Benefits

Topic: Life Saving Drugs Program

Type of Question: Hansard Page 44, 1 March 2017

Senator: Di Natale, Richard

Question:

Senator DI NATALE: What about the 2015-16 period?

Ms Shakespeare: I would need to take that on notice.

Mr Stuart: There were three in calendar year 2015, but I am not certain whether it was in the first or second half of the calendar year.

Senator DI NATALE: I will ask you to take that on notice. Could you tell me what the spending on the Life Saving Drugs Program looks like over the last four years? Let us look at the forward estimates.

Answer:

During 2015-16 financial year, three drugs were listed on the Life Saving Drugs Program (LSDP):

- Myozyme (alglucosidase alfa) for treatment of Adult Late-onset Pompe Disease (listed 1 September 2015)
- Elelyso (taliglucerase) for the treatment of Gaucher Disease Type I (listed 1 October 2015)
- Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia Type I (listed 1 June 2016)

The question regarding spending on the LSDP was answered, with the answers recorded in Hansard on page 44.